Physician profile
Peter H Forman
NPI 1003905480
$10,163.10
in general payments reported to CMS, 2019-2025
49 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $1,038 · 2021: $1,432 · 2022: $1,737 · 2023: $1,308 · 2024: $2,007 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,558 · Travel and Lodging: $255 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,557.90 |
| Travel and Lodging | $254.82 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,785.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $904.30 | 2019-2025 | Ozempic, Rybelsus, Rivfloza |
| Abbvie INC. | $692.08 | 2019-2025 | |
| Glaxosmithkline, LLC. | $653.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Pfizer INC. | $628.86 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $512.05 | 2021-2025 | |
| Gilead Sciences, INC. | $452.63 | 2019-2025 | Yeztugo |
| Medtronic, INC. | $436.14 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.78 | 2019-2025 | Jardiance |
| Amgen INC. | $311.82 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $275.56 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sanofi Pasteur INC. | $239.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $235.79 | 2019-2023 | |
| Abbott Laboratories | $227.20 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $211.14 | 2019-2025 | Mounjaro, Jardiance |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Forman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.